Phase 1 Completed N=36 Other

Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults

Healthy Volunteer

Source: ClinicalTrials.gov NCT01634191 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2021

Primary outcomePrimary: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast — 2832; 3235 h*ng/mL

Summary

The purpose of the study is to evaluate the effects of age and sex on the pharmacokinetics and safety of a single oral dose of 30 mg apremilast in healthy adults.

Outcome Measures

Outcome	Result	p-value
PRIMARY Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast	2832; 3235	—
PRIMARY AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast by Sex	2634; 3382	—
PRIMARY Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast	2900; 3323	—
PRIMARY AUC From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast by Sex	2673; 3499	—
PRIMARY Maximum Observed Plasma Concentration (Cmax) of Apremilast	302; 321	—
PRIMARY Maximum Observed Plasma Concentration of Apremilast by Sex	299; 322	—
PRIMARY Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast	2.50; 2.50	0.153
PRIMARY Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast by Sex	2.5; 2.75	0.169
PRIMARY Estimate of Terminal Elimination Half-life of Apremilast in Plasma (t1/2)	9.41; 9.15	—
PRIMARY Estimate of Terminal Elimination Half-life of Apremilast in Plasma by Sex	8.06; 10.3	—
PRIMARY Apparent Total Plasma Clearance When Dosed Orally (CL/F) of Apremilast	10.4; 9.03	—
PRIMARY Apparent Total Plasma Clearance When Dosed Orally of Apremilast by Sex	11.2; 8.57	—
PRIMARY Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast	136; 115	—
PRIMARY Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast by Sex	128; 123	—
SECONDARY Number of Participants With Adverse Events	2; 1; 2; 5; 2; 1	—

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria for elderly group

Healthy male or female subjects of any ethnic origin between ages of 65 and 85 inclusive with a body mass index (BMI) between 18 and 35.
Females must have been surgically sterilized at least 6 months prior to screening or be postmenopausal (to be confirmed by lab tests).
Males must agree to use latex or polyurethane condoms when engaging in sex during the study and for at least 28 days after dosing.
Elderly subjects with stable, chronic medical condition may be eligible if the condition is well-controlled and medications do not interfere with study procedures or pharmacokinetic interpretation

Inclusion Criteria for younger group:

Healthy male or female of any ethnic origin between the ages of 18 and 55 inclusive with a BMI between 18 and 35.
Males must agree to use latex or polyurethane condoms when engaging in sex during the study and for at least 28 days after dosing.
Females who are able to become pregnant have a negative pregnancy test at screening and baseline, and must agree to use one of the following:
a highly effective form of contraception (ex. Non-oral hormonal, intrauterine device) OR
oral hormonal contraceptive plus one additional form of barrier contraception OR
two forms of barrier contraception These must be effective by the time of screening. For younger females who are not able to become pregnant, the conditions for the elderly females will apply.

Exclusion Criteria

Any condition, including the presence of laboratory abnormalities, or psychiatric illness, that would prevent the subject from signing the Informed Consent form, places the subject at unacceptable risk if he were to participate in the study, or confounds the ability to interpret data from the study.
Presence of any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion, or plans to have elective or medical procedures during the conduct of the trial.
Exposure to an investigational drug (new chemical entity) within 30 days prior to the first dose administration or 5 half-lives of that investigational drug, if known (whichever is longer).
Subjects with known serum hepatitis, is a known carrier of hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus antibody.
Subjects who have used prescription systemic or topical medications within 30 days of dosing, unless it is being used to treat a stable, chronic medical condition. This includes medication that is an inhibitor or inducer of P-glycoprotein transporter and CYP-3A4/5 used within 14 days of dosing.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01634191). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.